Follow us on
Search News Archives
Conferences | Events
Lab Bulletin Media Partners
ERT

ERT

ERT

Products

Contact ERT


If you have not logged into the website then please enter your details below.

All articles from ERT

  ERT Enhances its Clinical Trial Imaging Team

ERTDavid Raunig, PhD brings decades of pharmaceutical research experience. ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, has announced the addition of David Raunig, PhD to its team of scientific and technological imaging experts. The science team is a key component of ERT’s rapidly growing advanced technology imaging solution, which has been used in more than 500 clinical studies to date...

 

  ERT Named Top 100 Solution Provider in mHealth

Innovative solutions drive long term healthcare programs and accelerate clinical development. ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced that it has been named to the Journal of mHealth’s annual Global Digital Health 100, an international benchmark for mobile, digital and connected technologies in healthcare. The Global Digital Health 100 is one of the HealthTech industry’s foremost technology award programs....

 

  ERT Acquires iCardiac Technologies

ERTCombined organization delivers innovative, efficient safety & efficacy solutions that support all phases of clinical development

ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, has announced it has acquired iCardiac Technologies, a leading provider of centralized cardiac safety and respiratory solutions that accelerate clinical research....

 

  ERT Support for New Drug Development Exceeds 10,000 Studies

Extensive experience enables biopharmaceutical researchers to better navigate clinical trial complexities and minimize risks

ERTERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it has reached a significant milestone in its nearly 50 year history: Global biopharmaceutical companies and contract research organizations (CROs) have relied on the company....

 

  ERT Acquires Biomedical Systems

Combined organization delivers proven, high tech solutions to accelerate clinical research

ERTERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, has announced it has acquired Biomedical Systems, a well-recognized provider of reliable imaging, as well as cardiac safety and respiratory data collection solutions....

 

  ERT Acquires Imaging Solution from Cleveland Clinic

Cloud-based imaging technology delivers compliant results without typical human bias

ERTERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the acquisition of ImageIQ, originally established as Cleveland Clinic’s Biomedical Imaging and Analysis Center. The acquisition enables ERT to offer advanced, end-to-end clinical trial imaging analysis using best-in-class technology that delivers compliant data for use in clinical development. “After conducting an exhaustive industry search...

 

  ERT Clinical Trial Oversight Selected by Premier Research

ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced that Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite as its trial management solution.

ERTClinical trials are becoming increasingly complex, due in part to an array of circumstances including the use of multiple data capture modalities and the need to evaluate more study endpoints than ever before. Additionally, global trials continue to be managed by a growing number of stakeholders, which heightens risks and uncertainties....

 

  ERT Recognized for Improving and Accelerating Clinical Research

Company Named Finalist for PACT Technology Company of the Year Award

ERTERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, has announced it has been named a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) Technology Company of the Year Award. ERT is one of only three companies nominated to receive this recognition....

 

  ERT Announces Appointment of New President and CEO ertLogoERT, a global technology-driven provider of clinical services and customizable medial devices to biopharmaceutical and healthcare organizations, announced today that its Board of Directors has appointed Jeffrey S. Litwin, M.D. its new President and Chief Executive Officer and as a member of the board...

 

  ERT Awarded over $10 Million of ePRO Business from Major Pharma - Increasing its Position as a Leading ePRO Provider ERT LogoERT, a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, announced today that it was awarded three new contracts with top tier pharmaceutical companies, totaling over $10 million for its electronic patient reported outcomes (ePRO) business. The company has been selected to provide its diverse multi-modality solutions, reinforcing its position as a leading provider of multi-mode ePRO devices and services...

 

  Chairman and Chief Scientist at ERT Recognized as One of 100 Most Inspiring People in the Life Sciences Industry ERT, a leading provider of centralized services to global pharmaceutical, biotechnology and medical device companies, announces that Joel Morganroth, MD, Chairman and Chief Scientist, has been acknowledged by PharmaVOICE magazine as one of the 100 most inspiring people in the life sciences industry. Dr. Morganroth has been recognized for his lifetime contribution to the advancement of individuals and science and the welfare of patients.

 

  ERT Agrees to Acquire the Research Services Business of CareFusion ERT (NASDAQ: ERES), a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, announced today that it has agreed to acquire the research services division of CareFusion Corporation (CRS), for $81 million in cash